Mutational Burden - 1294570

Sat, 06/09/2018 - 08:47

In my continual education, I learned that the measure of PD-1 is an indication of likelihood of effectiveness of immunotherapy. The anecdotal belief is that immunotherapy is not a viable option for ALK or EGFR patients. Some data is emerging to contradict such belief. I viewed one of the GRACE video with the question: are there better indicator than PD-1 level. The words "mutational burden" is used. In layman's term....

*what is mutational burden? The different type of mutations one has? So if one has EGFR and then T-790 and then something else...is that 3 different mutation burden?

*as the number of mutation type increases, does PD-1 measure increases? has there been study to show correlation between the "mutation burden" and PD-1 % measures?

Forums
Revision log message
Created by FeedsNodeProcessor

JimC

Hi wadvocator,

Tumor mutational burden encompasses more detail than just whether one's cancer has an EGFR, ALK or T790M mutation. It's the total of all of the mutations that a tumor may have acquired over the course of its development. There are a couple of good descriptions of TMB and its potential use as a biomarker for immunotherapy here:

https://www.bms.com/assets/bms/us/en-us/pdf/Disease-State-Info/tmb-101-…
https://www.scientificamerican.com/custom-media/tumor-mutation-burden/

JimC
Forum moderator